Munveer S Bhangoo1, Darren Sigal2. 1. Scripps Clinic, Division of Hematology-Oncology, 10666 North Torrey Pines Road, La Jolla, CA, 92037, USA. 2. Scripps Clinic, Division of Hematology-Oncology, 10666 North Torrey Pines Road, La Jolla, CA, 92037, USA. sigal.darren@scrippshealth.org.
Abstract
PURPOSE OF REVIEW: In this review, we highlight the pre-clinical development, recent clinical studies, and future directions of larotrectinib in patients with NTRK fusion-positive tumors. RECENT FINDINGS: The tropomyosin receptor kinase family, TrkA, TrkB, and TrkC, transmit extracellular signals via a variety of intracellular pathways to promote normal neuronal development. TrkA, B, and C are encoded by NTRK1, 2, and 3, respectively. NTRK chromosomal alterations, most commonly gene fusions, have been identified as driver mutations in a broad range of malignancies. Small molecule tyrosine kinase inhibitors of Trk, including larotrectinib, have shown broad clinical activity across multiple tumor types with NTRK fusion events. Although the prevalence of NTRK alterations is low, the exceptional activity of larotrectinib makes NTRK alterations an important predictive biomarker to screen for in any cancer.
PURPOSE OF REVIEW: In this review, we highlight the pre-clinical development, recent clinical studies, and future directions of larotrectinib in patients with NTRK fusion-positive tumors. RECENT FINDINGS: The tropomyosin receptor kinase family, TrkA, TrkB, and TrkC, transmit extracellular signals via a variety of intracellular pathways to promote normal neuronal development. TrkA, B, and C are encoded by NTRK1, 2, and 3, respectively. NTRK chromosomal alterations, most commonly gene fusions, have been identified as driver mutations in a broad range of malignancies. Small molecule tyrosine kinase inhibitors of Trk, including larotrectinib, have shown broad clinical activity across multiple tumor types with NTRK fusion events. Although the prevalence of NTRK alterations is low, the exceptional activity of larotrectinib makes NTRK alterations an important predictive biomarker to screen for in any cancer.
Authors: Cristina Tognon; Stevan R Knezevich; David Huntsman; Calvin D Roskelley; Natalya Melnyk; Joan A Mathers; Laurence Becker; Fatima Carneiro; Nicol MacPherson; Doug Horsman; Christopher Poremba; Poul H B Sorensen Journal: Cancer Cell Date: 2002-11 Impact factor: 31.743
Authors: Alexander Drilon; Ramamoorthy Nagasubramanian; James F Blake; Nora Ku; Brian B Tuch; Kevin Ebata; Steve Smith; Veronique Lauriault; Gabrielle R Kolakowski; Barbara J Brandhuber; Paul D Larsen; Karyn S Bouhana; Shannon L Winski; Robyn Hamor; Wen-I Wu; Andrew Parker; Tony H Morales; Francis X Sullivan; Walter E DeWolf; Lance A Wollenberg; Paul R Gordon; Dorothea N Douglas-Lindsay; Maurizio Scaltriti; Ryma Benayed; Sandeep Raj; Bethany Hanusch; Alison M Schram; Philip Jonsson; Michael F Berger; Jaclyn F Hechtman; Barry S Taylor; Steve Andrews; S Michael Rothenberg; David M Hyman Journal: Cancer Discov Date: 2017-06-03 Impact factor: 39.397
Authors: Robert C Doebele; Lara E Davis; Aria Vaishnavi; Anh T Le; Adriana Estrada-Bernal; Stephen Keysar; Antonio Jimeno; Marileila Varella-Garcia; Dara L Aisner; Yali Li; Philip J Stephens; Deborah Morosini; Brian B Tuch; Michele Fernandes; Nisha Nanda; Jennifer A Low Journal: Cancer Discov Date: 2015-07-27 Impact factor: 39.397
Authors: Munveer S Bhangoo; Peter Boasberg; Pareen Mehta; Julia A Elvin; Siraj M Ali; Winnie Wu; Samuel J Klempner Journal: Oncologist Date: 2018-01-31
Authors: A Vaishnavi; M Capelletti; P A Jänne; R C Doebele; A T Le; S Kako; M Butaney; D Ercan; S Mahale; K D Davies; D L Aisner; A B Pilling; E M Berge; J Kim; H Sasaki; S Park; G Kryukov; L A Garraway; Peter S Hammerman; J Haas; S W Andrews; D Lipson; P J Stephens; V A Miller; M Varella-Garcia Journal: Nat Med Date: 2013-10-27 Impact factor: 53.440
Authors: Steven G DuBois; Theodore W Laetsch; Noah Federman; Brian K Turpin; Catherine M Albert; Ramamoorthy Nagasubramanian; Megan E Anderson; Jessica L Davis; Hope E Qamoos; Mark E Reynolds; Scott Cruickshank; Michael C Cox; Douglas S Hawkins; Leo Mascarenhas; Alberto S Pappo Journal: Cancer Date: 2018-09-11 Impact factor: 6.860
Authors: Nathan Griffin; Mark Marsland; Severine Roselli; Christopher Oldmeadow; John Attia; Marjorie M Walker; Hubert Hondermarck; Sam Faulkner Journal: Biomolecules Date: 2020-09-17